A Study to Evaluate the Pharmacokinetics and Safety of ASP015K in Healthy Chinese Subjects

Phase 1 Completed 36 enrolled Astellas Pharma Inc

RandomizedSequentialOpen-labelBasic science

Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of ASP015K after single-dose and multiple-dose administration in healthy Chinese participants.

Timeline

Start: 2019-12-05
Primary completion: 2020-12-21
Completion: 2020-12-21

Publications

Gao X, He X, Oshima H, Miyatake D, Otsuka Y, Kato K, Cai C, Wojtkowski T, Song N, Kaneko Y, Shi A. Pharmacokinetics and Safety of Single and Multiple Doses of Peficitinib (ASP015K) in Healthy Chinese Subjects. Drug Des Devel Ther. 2022 May 9;16:1365-1381. doi: 10.2147/DDDT.S359501. eCollection 2022.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	peficitinib	Small molecule	50 mg	Oral
Subject	peficitinib	Small molecule	100 mg	Oral
Subject	peficitinib	Small molecule	150 mg	Oral

Indications

No indication recorded.